Krystal Biotech, Inc. - צמיחת הכנסות ב-12 חודשים נגררים KRYS

Krystal Biotech, Inc. (KRYS) maintains stability through a closed-loop gene dermatology ecosystem with high customer switching costs. The development of therapies for rare skin pathologies using herpes viruses paves the way into ophthalmology, while in-house manufacturing scales revenue and reduces costs. Comparative year-over-year sales dynamics over a rolling period confirm this trend, where the parameter value equals 26.30.
פילוחי נתונים אנליטיים מרוכזים עבור Krystal Biotech (KRYS)

This indicator calculates revenue dynamics over the last twelve months, enabling the rapid identification of fundamental business deviations between quarterly reports. For Krystal Biotech, Inc. (KRYS), this pace reflects the commercialization of gene therapy, where patients' lifelong need for treatment creates a steady revenue stream. By analyzing this chart of rolling 12-month YoY revenue growth, an investor can see the actual scaling speed of the rent-seeking asset. A stable trend confirms the long-term viability of the business model.